Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1969 3
1970 2
1971 1
1974 2
1976 1
1977 2
1978 2
1979 2
1981 1
1983 2
1984 1
1985 1
1986 3
1987 1
1988 1
1990 4
1991 2
1992 4
1993 7
1994 13
1995 7
1996 6
1997 8
1998 6
1999 6
2000 8
2001 14
2002 9
2003 8
2004 14
2005 22
2006 18
2007 22
2008 14
2009 24
2010 22
2011 27
2012 33
2013 21
2014 28
2015 29
2016 28
2017 38
2018 40
2019 32
2020 65
2021 53
2022 37
Text availability
Article attribute
Article type
Publication date

Search Results

637 results
Results by year
Filters applied: . Clear all
Page 1
Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U, Parakh S, Gan HK, Scott AM. Hafeez U, et al. Among authors: scott am. Molecules. 2020 Oct 16;25(20):4764. doi: 10.3390/molecules25204764. Molecules. 2020. PMID: 33081383 Free PMC article. Review.
Antibody therapy of cancer.
Scott AM, Wolchok JD, Old LJ. Scott AM, et al. Nat Rev Cancer. 2012 Mar 22;12(4):278-87. doi: 10.1038/nrc3236. Nat Rev Cancer. 2012. PMID: 22437872 Review.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: scott am. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, Dehairs J, Burvenich IJG, Zadra G, Chetta PM, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokiou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM. Centenera MM, et al. Among authors: scott am. Cancer Res. 2021 Apr 1;81(7):1704-1718. doi: 10.1158/0008-5472.CAN-20-2511. Epub 2021 Feb 5. Cancer Res. 2021. PMID: 33547161
Probiotics for preventing acute otitis media in children.
Scott AM, Clark J, Julien B, Islam F, Roos K, Grimwood K, Little P, Del Mar CB. Scott AM, et al. Cochrane Database Syst Rev. 2019 Jun 18;6(6):CD012941. doi: 10.1002/14651858.CD012941.pub2. Cochrane Database Syst Rev. 2019. PMID: 31210358 Free PMC article.
Care Transitions From Patient and Caregiver Perspectives.
Mitchell SE, Laurens V, Weigel GM, Hirschman KB, Scott AM, Nguyen HQ, Howard JM, Laird L, Levine C, Davis TC, Gass B, Shaid E, Li J, Williams MV, Jack BW. Mitchell SE, et al. Among authors: scott am. Ann Fam Med. 2018 May;16(3):225-231. doi: 10.1370/afm.2222. Ann Fam Med. 2018. PMID: 29760026 Free PMC article.
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
Nassar ZD, Mah CY, Dehairs J, Burvenich IJ, Irani S, Centenera MM, Helm M, Shrestha RK, Moldovan M, Don AS, Holst J, Scott AM, Horvath LG, Lynn DJ, Selth LA, Hoy AJ, Swinnen JV, Butler LM. Nassar ZD, et al. Among authors: scott am. Elife. 2020 Jul 20;9:e54166. doi: 10.7554/eLife.54166. Elife. 2020. PMID: 32686647 Free PMC article.
637 results